Nuacht

24/7 Wall St.44 nóiméad

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Explore The Weight Loss & Diabetes Drug Battle: Ozempic Vs. Mounjaro Vs. Wegovy

Mounjaro (tirzepatide) : Lilly's dual GIP/GLP-1 agonist has delivered best-in-class weight loss and glycemic control in T2D and, under its obesity brand Zepbound , has outperformed semaglutide in head ...
Yahoo Finance7 uair an chloig

The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know

Here's what investors need to know. On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had ...

Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

FDA approves Wegovy to treat serious liver disease

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...